In a video interview with Pharma Commerce, Delphine Perridy, chief commercial officer, Envirotainer, noted that the pharmaceutical industry is undergoing significant evolution driven by unmet patient needs, rapid scientific advancements, and the emergence of new technologies. Innovations such as gene therapies, precision medicines, and advancements in obesity treatment with GLP-1s exemplify this shift. Additionally, the integration of artificial intelligence in drug discovery is streamlining research and development processes, lowering costs, and accelerating time to market. As a result, pharmaceutical companies must adapt their business models to ensure that newly approved drugs reach patients worldwide more efficiently. Perridy also shared why ultra-precise temperature control and customized logistics solutions are so critical when it comes to biologics and personalized medicine; why has the demand for sustainable practices has risen exponentially; Where she believes the pharma cold chain is heading in the next few years in terms of technological breakthroughs and market dynamic shifts.
A transcript of Perridy’s conversation with PC can be found below.
PC: Why has the demand for sustainable practices risen exponentially, and what has Envirotainer been doing in this regard?
Perridy: I think that sustainability is an increasing request from pharma manufacturers. I think that the pressure is coming from government, from regulatory bodies. There is an increasing social awareness of the issues globally. This is why it’s such an important topic. At Envirotainer, we really prioritize sustainability in its strategy. Seeing that we are guided by science-based targets, we have set the most ambitious targets in the industry to really lower our CO2 emissions. That’s a commitment for us.
We are also developing our solutions with sustainability in mind. For example, we are trying to focus on lowering the weight of the units and optimizing the footprint inside the aircraft, while also trying to reduce the flow of empty container units. We have also worked with some of our partners to really develop CO2 calculation tools so that we can really work with our pharma customers to measure the CO2 emissions on the specific trade. lanes during a specific shipment. We try to keep sustainability in mind, as we are innovating in this area and working with our pharma partners.